Simon Greulich1, Daniel Kitterer1, Joerg Latus1, Eissa Aguor1, Hannah Steubing1, Philipp Kaesemann1, Alexandru Patrascu1, Andreas Greiser1, Stefan Groeninger1, Agnes Mayr1, Niko Braun1, M Dominik Alscher1, Udo Sechtem1, Heiko Mahrholdt2. 1. From the Division of Cardiology (S.G., H.S., P.K., A.P., U.S., H.M.) and Division of Nephrology, Department of Internal Medicine (D.K., J.L., N.B., M.D.A.), Robert-Bosch-Medical Center Stuttgart, Germany; Philips Medical Solutions, Best, The Netherlands (E.A.); Siemens Healthcare GmbH, Erlangen, Germany (A.G., S.G.); and Division of Radiology, University Hospital Innsbruck, Austria (A.M.). 2. From the Division of Cardiology (S.G., H.S., P.K., A.P., U.S., H.M.) and Division of Nephrology, Department of Internal Medicine (D.K., J.L., N.B., M.D.A.), Robert-Bosch-Medical Center Stuttgart, Germany; Philips Medical Solutions, Best, The Netherlands (E.A.); Siemens Healthcare GmbH, Erlangen, Germany (A.G., S.G.); and Division of Radiology, University Hospital Innsbruck, Austria (A.M.). Heiko.Mahrholdt@rbk.de.
Abstract
BACKGROUND: Cardiac sarcoidosis (CS) may manifest as arrhythmia or even sudden cardiac death. Because patients with CS often present with nonspecific symptoms, normal electrocardiography, and preserved left ventricular ejection fraction, a reliable diagnostic tool for the work-up of CS is needed. Late gadolinium enhancement-cardiovascular magnetic resonance has proven diagnostic value in CS but has some limitations that may be overcome by adding newer cardiovascular magnetic resonance mapping techniques. The aim of our study was to evaluate a comprehensive cardiovascular magnetic resonance protocol, including late gadolinium enhancement and mapping sequences in sarcoid patients with no symptoms or unspecific symptoms and preserved left ventricular ejection fraction. METHODS AND RESULTS: Sixty-one sarcoid patients were prospectively enrolled and underwent comprehensive cardiovascular magnetic resonance imaging. Twenty-six healthy volunteers served as control group. Mean left ventricular ejection fraction was 65%; late gadolinium enhancement was only present in sarcoid patients (n=15). Sarcoid patients had a higher median native T1 (994 versus 960 ms; P<0.001), lower post contrast T1 (491 versus 526 ms; P=0.001), expanded extracellular volume (28 versus 25%; P=0.001), and higher T2 values (52 versus 49 ms; P<0.001) compared with controls. Among patients with values higher than the 95% percentile of healthy controls, most significant differences were observed for native T1 and T2 values. Most of these patients were late gadolinium enhancement negative. CONCLUSIONS: Patients with sarcoidosis demonstrate higher T1, extracellular volume, and T2 values compared with healthy controls, with most significant differences for native T1 and T2. While promising, the clinical significance of the newer mapping techniques with respect to early diagnosis and therapy of CS will have to be determined in future studies.
BACKGROUND:Cardiac sarcoidosis (CS) may manifest as arrhythmia or even sudden cardiac death. Because patients with CS often present with nonspecific symptoms, normal electrocardiography, and preserved left ventricular ejection fraction, a reliable diagnostic tool for the work-up of CS is needed. Late gadolinium enhancement-cardiovascular magnetic resonance has proven diagnostic value in CS but has some limitations that may be overcome by adding newer cardiovascular magnetic resonance mapping techniques. The aim of our study was to evaluate a comprehensive cardiovascular magnetic resonance protocol, including late gadolinium enhancement and mapping sequences in sarcoid patients with no symptoms or unspecific symptoms and preserved left ventricular ejection fraction. METHODS AND RESULTS: Sixty-one sarcoid patients were prospectively enrolled and underwent comprehensive cardiovascular magnetic resonance imaging. Twenty-six healthy volunteers served as control group. Mean left ventricular ejection fraction was 65%; late gadolinium enhancement was only present in sarcoid patients (n=15). Sarcoid patients had a higher median native T1 (994 versus 960 ms; P<0.001), lower post contrast T1 (491 versus 526 ms; P=0.001), expanded extracellular volume (28 versus 25%; P=0.001), and higher T2 values (52 versus 49 ms; P<0.001) compared with controls. Among patients with values higher than the 95% percentile of healthy controls, most significant differences were observed for native T1 and T2 values. Most of these patients were late gadolinium enhancement negative. CONCLUSIONS:Patients with sarcoidosis demonstrate higher T1, extracellular volume, and T2 values compared with healthy controls, with most significant differences for native T1 and T2. While promising, the clinical significance of the newer mapping techniques with respect to early diagnosis and therapy of CS will have to be determined in future studies.
Authors: Brendan L Eck; Scott D Flamm; Deborah H Kwon; W H Wilson Tang; Claudia Prieto Vasquez; Nicole Seiberlich Journal: Prog Nucl Magn Reson Spectrosc Date: 2020-11-06 Impact factor: 9.795
Authors: Karl P Kunze; Ralf J Dirschinger; Hans Kossmann; Franziska Hanus; Tareq Ibrahim; Karl-Ludwig Laugwitz; Markus Schwaiger; Christoph Rischpler; Stephan G Nekolla Journal: J Cardiovasc Magn Reson Date: 2018-05-24 Impact factor: 5.364
Authors: Riina Kandolin; Kaj Ekström; Trevor Simard; Benjamin Hibbert; Pablo Nery; Jukka Lehtonen; Markku Kupari; David Birnie Journal: Oxf Med Case Reports Date: 2019-05-31
Authors: G J H Snel; M van den Boomen; L M Hernandez; C T Nguyen; D E Sosnovik; B K Velthuis; R H J A Slart; R J H Borra; N H J Prakken Journal: J Cardiovasc Magn Reson Date: 2020-05-11 Impact factor: 5.364
Authors: Andrea Baggiano; Alberico Del Torto; Marco Guglielmo; Giuseppe Muscogiuri; Laura Fusini; Mario Babbaro; Ada Collevecchio; Rocco Mollace; Stefano Scafuri; Saima Mushtaq; Edoardo Conte; Andrea Daniele Annoni; Alberto Formenti; Maria Elisabetta Mancini; Giulia Mostardini; Daniele Andreini; Andrea Igoren Guaricci; Mauro Pepi; Marianna Fontana; Gianluca Pontone Journal: Diagnostics (Basel) Date: 2020-09-29